Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

SHANGHAI and BOSTON, Nov. 6, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced it will ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, has been selected as a late breaking abstract to present Phase II interim data ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Silence Therapeutics has unveiled ...

Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further strengthen cardiovascular portfolio and enter dynamic field of ...

In February 2026, Sarepta Therapeutics announced that New Zealand’s Medsafe approved its clinical trial application for INSIGHTT, a first-in-human Phase 1 study of SRP-1005, an investigational siRNA ...

SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...

German pharma giant Bayer AG BAYRY has entered into a collaboration and global licensing agreement with Soufflé Therapeutics to develop a heart-targeted small interfering RNA (siRNA) therapy in a move ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

The FDA approved plozasiran (Redemplo) for the reduction of triglycerides in people with familial chylomicronemia syndrome (FCS), the agency announced. The small interfering RNA (siRNA) therapy, ...